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Today the situation is much reversed with radiotherapeu-
tics growing into a market worth many 10’s of billions.1 Two 
agents have recently been approved by the FDA for clinical 
use, i.e. Radium-223 dichloride (Xofigo®—indicated for the 
treatment of patients with castration-resistant prostate can-
cer, symptomatic bone metastases and no known visceral 
metastatic disease) and Lutetium Lu-177 DOTATATE (LU-
TATHERA®—indicated for the treatment of somatostatin 
receptor-positive gastroenteropancreatic neuroendocrine 
tumours—GEPNETs). In addition, there are several work-
ing groups in the UK [Internal Dosimetry Users Group—
IDUG; Clinical and Translational Radiotherapy Research 
Working Group–CTRad, British Nuclear Medicine Society 
(BNMS) molecular radiotherapy group] and internation-
ally (Internal Dosimetry Task Force of the European As-
sociation of Nuclear Medicine and the Society of Nuclear 
Medicine and Molecular Imaging Medical Internal Radia-
tion Dose Committee) advocating the utility of MRT.
Radioiodine therapies still form the backbone of the 
MRT services in the UK, with 223Ra, 90Y-SIRT and 
peptide receptor radionuclide therapy (e.g. Lu-177 
DOTATATE) now becoming routine services. As the 
number and variety of MRT procedures advances along-
side renewed calls for improved planning of these ther-
apies, taking advantage of the increased quantitative 
accuracy of radioisotope imaging, the nuclear medicine 
community is facing a paradigm shift in the manage-
ment of MRT. Improvement of the MRT service requires 
input from a multidisciplinary team. The National 
Cancer Research Institute (NCRI)’s CTRad published 
a review of MRT research in the UK in 2016.2 The 
report identifies three strategic priorities and provides a 
number of recommendations for each that will promote 
progress in MRT research. The report addresses the 
need to enhance research infrastructure and multidis-
ciplinary working and for more multicentre MRT trials 
with a national QA programme to standardize methods 
between centres. It also pointed out that staff need more 
time to devote to building and providing a dosimetry 
service for individualized MRT treatment planning. 
Realizing the unfulfilled potential of MRT will require 
an integrated approach, increased investment and the 
active involvement of a range of individuals and organi-
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It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux 
(2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or 
internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent 
NCRI–CTRad (Clinical Trials in Molecular Radiotherapy–Tribulations and Triumphs) meeting, held in London on the 8 
June 2018. The meeting was organized by the NCRI–CTRad to review the challenges and opportunities for clinical trials 
in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and 
to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear 
Medicine Society and reflects the progress of Nuclear Medicine in the UK.
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Here, we report on the recent NCRI–CTRad (Clinical Trials 
in Molecular Radiotherapy—Tribulations and Triumphs) 
meeting, held in London on the 8 June 2018. The meeting was 
organized by the NCRI–CTRad to review the challenges and 
opportunities for clinical trials in MRT, particularly focussing 
on investigator-led trials that incorporate imaging and dosim-
etry, and to discuss how the community can move forward. 
This meeting was organized in conjunction with the BNMS 
and reflects the progress of Nuclear Medicine in the UK. Ulti-
mately the aim was to connect individuals from disparate 
disciplines working in the field of MRT. By facilitating a plat-
form to discuss research interests and by critically evaluating 
ongoing clinical trials in MRT it was hoped to initiate new 
multidisciplinary collaborative efforts to progress this field. 
This meeting further underscored the role of CTRad in aiding 
the development of research ideas into funded clinical studies.
PreSentatIonS
The changing landscape of molecular radiotherapy
Professor John Buscombe, Consultant Nuclear Medicine 
Physician at Cambridge University Hospitals and current 
president of the BNMS, opened the meeting by providing 
a historical overview of the role of Nuclear Medicine in the 
changing and challenging landscape of MRT. Nuclear Medi-
cine became a mono-speciality in 1989, yet there still remains 
a large variation in Nuclear Medicine departments with few 
centres equipped to provide therapy beyond the use of 131I 
in the treatment of differential thyroid cancer (DTC). The 
success of the NETTER-1 study3 was highlighted, yet in stark 
contrast and despite the use of peptide receptor radionuclide 
therapy over the past 20 years in many nuclear medicine 
centres in the UK, there is a lack of funding and support from 
national bodies such as the National Institute for Health and 
Clinical Excellence. Notwithstanding this lack of funding and 
investment, the use of theragnostic approaches (68Ga-PSMA 
/ 177Lu-PSMA) in the treatment of metastatic castrate-resis-
tant prostate cancer (mCRPC) is fast gaining ground, with the 
first-in-man treatment concept using the imaging–therapy 
pair 68Ga-PSMA/213Bi-PSMA, recently reported.4 There are a 
plethora of new MRT constructs entering clinical trials with 
heavy investment worldwide in MRT and MRT centres. To 
accelerate this global trend in the UK, specialists are required 
to support the drive for MRT and more robust clinical trials 
are needed which again emphasizes the need for funding.
Professor Joe O’Sullivan, Consultant Oncologist at Queens 
University, Belfast gave a presentation entitled MRT for 
bone metastases from prostate cancer. Approximately 90% of 
patients with CRPC have bone metastases, which is also the 
main cause of death in this patient group. The phenotype of 
prostate cancer in bone facilitates both imaging and therapy. 
Bone seeking radionuclides can be classified either as calcium 
analogues (89Sr or 223Ra) or attached to a phosphate (153Sm 
EDTMP, 186Re HEDP, 188Re or 32Ph). Clinical trials with 
single agent β-emitting radionuclides have been limited by 
haematological toxicity and although showing a 40–60% pain 
response rate after therapy, there has been no demonstrable 
survival benefit. On the other hand, the ALSYMPCA trial 
with 223Ra showed an increased overall survival benefit with 
little associated toxicity.5,6 To improve the therapeutic ratio of 
223Ra, the ERA-223 trial initiated in 2016 evaluated the use of 
Abiraterone in conjunction with 223Ra. However, due to the 
large number of bone fractures seen with the combined treat-
ment recruitment was stopped. This trial highlighted the need 
for timing of the combined therapy, which was taken on board 
in the design of the ADRRAD trial (Belfast) where Docetaxel 
is given prior to the 223Ra cycles.7 At the time of writing, no 
unexpected or dose limiting toxicities have been observed in 
the 29/30patients recruited. He concluded that a new era for 
bone targeting with MRTs has commenced, but that many 
questions regarding the value and safety of combination ther-
apies, initiation of therapy in the CRPC disease course, the 
response assessment either using whole body MRI or PSMA 
PET detection and interaction between 223Ra and the bone 
microenvironment, remain unanswered.
Dr Kim Orchard, Consultant Haematologist from South-
ampton, gave a detailed overview of their Trial experience with 
anti-CD66 for myeloma, outlining the role of radiotherapy in 
bone marrow transplantation. Traditionally, transplant condi-
tioning schedules have involved the use of total body irradia-
tion for disease eradication. However, this is associated with 
high toxicity and an alternative is the use of targeted radio-
therapy with a radiolabelled anti-CD66 monoclonal antibody. 
Anti-CD66 is bound in the bone marrow and therefore provides 
a useful target for bone marrow conditioning. 111In-labelled 
anti-CD66 is used for biodistribution and dosimetry determi-
nation. If dosimetry outcomes were favourable, treatment uses 
90Y as the therapeutic isotope. Dose escalation was performed 
to determine the maximum tolerated dose in a Phase 1 trial, 
prior to proceeding to Phase 2. For patients in Phase 2, up to 
35 Gy was delivered to the bone marrow, and a linear relation-
ship obtained between infused activity of 90Y and the radiation 
dose delivered to the bone marrow.
Following the success of this treatment, the principle has 
now been extended to a paediatric trial in relapsed/refrac-
tory leukaemia, between Great Ormond Street Hospital and 
University College London Hospital. This is a dose escalating 
protocol prior to allogenic haematopoietic stem cell transplan-
tation, with activity levels of 35, 45, 50 and 55 MBq/Kg. The 
trial is currently underway with successful implementation at 
the lower activity levels.
Dosimetry and radiochemistry
Dr Matthew Aldridge, University College London Hospitals, 
highlighted the need for dosimetry in his talk entitled Dosim-
etry for MRT. The concept of theragnostics was introduced, 
emphasizing the principle of disease staging with imaging of a 
radiopharmaceutical, followed by therapy with the therapeutic 
version. However, despite this personalised approach, there 
is still an uncertain relationship between the administered 
activity (in GBq) and the absorbed radiation dose (in Gy) to 
both the tumour and the normal tissues, which, if evaluated, 
would render the treatment more personalized, with poten-
tially improved outcomes. It was shown that whilst there is a 
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good correlation between tumour absorbed dose and response, 
there is in fact, a wide range of tumour absorbed doses for a 
given activity and the appropriate modulation of treatments 
would likely bring MRT into the realm of conventional radio-
therapy with tumour control probability balanced against 
normal tissue damage. The methodology of performing MRT 
dosimetry was presented, as well as the resource implications—
including extra imaging sessions—that are required. However, 
this initial investment must be balanced by the improved 
patient outcomes and associated financial benefits, including 
the reduced related disease complications of a successful 
treatment. In addition, resource intensive MRT treatments 
may be contraindicated if dosimetry indicates unfavourable 
tumour absorbed doses. MRT dosimetry is conceptually easy 
to perform, and satisfies NHS forward planning of biomarker 
driven, personalized treatments with demonstrable outcomes 
that will significantly aid the NHS deliverable of improving 
cancer survival rates.
Dr Joseline Tan, Head of Radiopharmacy at the Royal Marsden 
NHS Foundation Trust presented a talk entitled Radiochem-
istry for MRT. Dr Tan introduced the radiopharmacy’s role in 
setting up clinical trials using radiopharmaceuticals and the 
challenges they need to overcome. The radiopharmacy plays a 
critical role in the acquisition, preparation, accountability and 
distribution of radiopharmaceuticals used in clinical research. 
Radiopharmacy-specific issues need to be considered for Clin-
ical Trial Investigational Medicinal products. Therefore, they 
need to be involved at the early stages of the trial setup and 
in the sponsor’s site feasibility assessment, as they will need 
to ensure they have the necessary staff, resources, processes, 
licenses and environment agency permits in place.
Dr Mark Gaze, Consultant Clinical Oncologist at University 
College London Hospitals and Great Ormond Street Hospital 
for Children, conferred the many tribulations and triumphs 
when conducting Clinical trials for children and young people. 
This is a challenging cohort of patients to treat, requiring a vast 
infrastructure associated with a multidisciplinary approach of 
treatment. The LUDO trial, a Phase 2 paediatric trial evalu-
ating the use of 177Lu-DOTATATE in a relapsed/refractory 
neuroblastoma, was presented. This trial demonstrated how 
dosimetry was used to modulate administered activities based 
on whole body absorbed doses. Tumour and organ at risk 
dosimetry was also assessed, and treatment was well tolerated 
in this heavily pre-treated cohort.
Whilst the triumph of using a novel treatment regimen within 
a clinical trial context was noted, the time scale of putting 
this trial into practice was regarded as a tribulation with 10 
years taken to develop the concept, obtain ethics applications/
approvals and then to conduct a trial with patient recruitment, 
data acquisition and data analysis. This is in keeping with regu-
latory requirements and clinical trial management but does 
negate the essential element of acquiring an evidence base as 
rapidly as possible. Given the time scales required to imple-
ment a clinical trial, it is prudent to commence conceptual-
ising new treatment protocols in parallel with existing ones. 
Whilst LUDO outcomes are being evaluated, a new option 
for relapsed/refractory neuroblastoma is available with the 
MiNiVan trial—a combination of 131I-mIBG, nivolumab and 
Dinutuximab β antibodies, which is the first transatlantic trial 
for this disease.
A further trial—Veritas—to open across Europe will evaluate the 
role of 131I-mIBG in neuroblastoma in a randomized trial with 
high-dose chemotherapy. In this trial, the role of MRT will also 
be implemented earlier in the treatment regime, after induction 
chemotherapy.
Clinical trials for differentiated thyroid cancer
Dr Kate Garcez, Consultant Clinical Oncologist at the Christie 
Hospital in Manchester and clinical lead for thyroid cancer, 
gave a presentation entitled Challenges for radioiodine treat-
ment of DTC. Radioiodine has been administered for over 40 
years to treat DTC. The administered activity depends on the 
patient’s risk stratification. The prognosis for low risk patients, 
treated with low radioiodine activities to ablate thyroid 
remnants following surgery, is excellent. However, radioiodine 
may be overtreating some of these patients leading to the IoN 
and ESTIMABL 2 trials.8,9 The optimal activity to treat high 
risk patients is unclear. Empirical activities of 3.5–5.5 GBq are 
commonly used. The absorbed dose to lesions ranges from <1 
to 100 Gy. There is a need to identify the threshold absorbed 
dose for successful treatment or to implement methods to 
administer as high as safely achievable activities in combina-
tion with lesion dosimetry to avoid under treatment of high-
risk patients.10,11 However, dosimetry is challenging in clinical 
practice due to the need for extra scanning and resources. 
More trials are required to assess the efficacy of dosimetry in 
treatment management. Dr Garcez concluded her presentation 
by stating that “In an era of increasingly precise delivery of 
radiation there is a need to better understand likely absorbed 
dose, in order to optimise [radioiodine] use in metastatic and 
high-risk patients.”
Dr Jon Wadsley, Consultant Clinical Oncologist at Weston 
Park Hospital and the Clinical Lead for the North Trent Cancer 
Research Network, opened this session with a summary of the 
challenges in setting up the SELIMETRY trial.12 The primary 
end point of this Phase 2 trial is to assess Selumetinib-en-
hanced radioiodine therapy in DTC patients that are refrac-
tory to radioiodine. Selumetinib is a MEK kinase inhibitor 
believed to allow re-expression of sodium iodide symporters 
and therefore allow the patient a further option of radioiodine 
treatment. The response to this therapy is likely to relate to 
the absorbed dose. This is the first multicentre trial to incor-
porate single-photon emission CT (SPECT/CT) based dosim-
etry and an exploratory endpoint is to assess the feasibility of 
this approach for treatment management. This is a relatively 
complex study, requiring the patient to have multiple3,4 quan-
titative 123I and 131I SPECT/CT scans that has been reflected 
in its expense.
The first network of centres capable of performing radioiodine 
SPECT/CT based dosimetry in a harmonized way is being set up 
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for the SELIMETRY trial. This network will ensure there is no 
bias in dosimetry results between centres.
Dr Rebecca Gregory, Principal Radioisotopes Physicist in the 
Joint Department of Physics at the Royal Marsden Hospital 
gave a presentation on Multicentre setup for dosimetry trials 
in the UK. Commercially available SPECT/CT systems are not 
currently set up to provide quantitative radioiodine imaging. 
Therefore SPECT/CT systems at each site were calibrated to 
convert the γ photon count rates to activities for use in dosim-
etry calculations. These count rates are not linear with activity 
for therapeutic activities (GBq) of 131I, therefore the count rate 
response of each system must be characterized to correct for 
this non-linearity. In addition to this partial volume effects 
need to be corrected for small objects. Therefore, volume 
specific calibration factors have also been measured. A library 
of calibration factors has been established at RMH so that trial 
images can be quantified, and dosimetry performed centrally. 
This is currently necessary to ensure that dosimetry is 
performed in a reproducible way to avoid method-related bias 
in the dosimetry results. The imaging and dosimetry network 
built for this trial will facilitate further studies.
The NCRI Radiotherapy Trials Quality Assurance (RTTQA) 
Team provides QA programmes for radiotherapy treatment 
planning of all UK Clinical Research Network Portfolio trials. 
External beam radiotherapy (EBRT) clinical trials currently 
undergo rigorous QA to ensure the safety, consistency and 
accuracy of delivered treatment. Elizabeth Miles, Coordinator 
for the RTTQA team, gave a presentation, RTTQA for MRT, 
outlining the QA process and the challenges of introducing 
similar procedures to MRT research. The QA process for EBRT 
involves a facility questionnaire and guidelines for image target 
and organ at risk outlining, treatment planning and optimiza-
tion, delivery and verification and dosimetry audit. Prior to 
data accrual, centres plan a benchmark case following the trial 
protocol and improve their adherence to the protocol on the 
RTTQA feedback. Dosimetry audits are used during accrual to 
ensure continued compliance. Centres are approved for plan-
ning specified anatomical sites for protocols used in multiple 
trials. Molecular radiotherapy is at the relatively early stage of 
building-up the evidence for best practice, compared to EBRT 
trials that have established guidelines. The MRT community 
needs to build on the EBRT experience and the RTTQA plan to 
incorporate similar QA processes into MRT dosimetry trials, 
to ensure accurate and consistent MRT dosimetry between 
centres.
movInG ForwardS
The session started with Dr Samantha Terry, Lecturer in 
Radiobiology at King's College London and Dr Nadia Falzone, 
Senior Research Physicist at the University of Oxford, high-
lighting the importance of radiobiology in MRT. Dr Terry 
illustrated the use of elegant cell-free DNA assays to evaluate 
the radiobiology of Auger electron-emitters in her talk enti-
tled Auger emitters for MRT. Auger electron-emitters when 
used as a radiopharmaceutical, could have great potential in 
the treatment of both cancer and infections. Due to the short 
range of the emitted electrons and high ionisation density at 
the site of decay, Auger electron-emitters are ideal in the treat-
ment of single cells and micrometastases due to their ability 
to provide precision radiotherapy with little off-target effect. 
She described the ability of 67Ga to damage DNA and kill 
cancer cells in vitro through both non-targeted and targeted 
approaches. With the availability of new gallium-chelators 
providing very high specific activities with facile radiolabelling 
conditions that could be easily implemented in the clinic, she 
concluded that 67Ga deserves further investigation as a thera-
peutic radionuclide in a range of cancers.
Dr Falzone’s presentation entitled Radiobiology for MRT, high-
lighted the importance of establishing radiobiological parameters 
for MRT constructs. Particularly, when using radionuclides that 
have a significant Auger electron component in their decay scheme 
and where these constructs internalize and locate to the nucleus 
of a cell. In this instance, adopting radiobiological sensitivity 
parameters α and β directly from external beam exposure, may 
not be accurate. There is a real challenge to evaluate the biological 
response for MRT constructs. To relate dose to biological effect, 
quantitative cell culture techniques are used. In itself, this presents 
a problem as firstly, accurate estimates of dose in the exposed cells 
are required. As with organ scale dosimetry, the Medical Internal 
Radiation Dose formulism13 can be used to determine dose. 
However both the decay spectra used for the radionuclide in ques-
tion and the geometry of the cancer cell can have a huge effect on 
dose assessment.14,15 Furthermore, due to the paucity of α/β ratio 
data for radionuclides, when relating the dose required to achieve a 
specific biological effective, α/β ratios for EBRT are used by simply 
accounting for dose protraction.16 This presumes that there is no 
difference in cell killing per unit dose between MRT and EBRT, i.e. 
that the α/β ratios are equivalent. These assumptions need to be 
confirmed for MRT. Dr Falzone concluded that there is a great need 
for fundamental research to expound the radiobiology specific to 
MRT.
The session concluded with Caroline Glover, Research Funding 
Manager at CRUK detailing different funding streams and funding 
opportunities within CRUK. She drew attention to the fact that 
CRUK currently only supports three MRT trials in the Clin-
ical Research Committee Portfolio of which two are focussed on 
thyroid cancer (IoN—Phase III and SELIMETRY—Phase II) while 
the other concerns neuroendocrine cancer (LuDo—Phase II). 
There is great scope for funding MRT trials and she called on the 
nuclear medicine community to put forward ambitious proposals 
which bring together the research community around a specific 
problem and which, if successful, would result in a significant step 
forward against the CRUK research strategy.
ConCLuSIon
In recent years, Molecular Radiotherapy has undergone a renais-
sance with an unprecedented expansion of radioligands for 
imaging and therapy. In the UK alone, several clinical trials that 
incorporate MRT, as highlighted here, are currently underway. This 
again underscores the importance of appropriate and adequate QA 
processes and the need to standardise dosimetry. There is also a 
growing realisation that dosimetry alone is not sufficient to realize 
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the full potential of MRT but that radiobiologically informed treat-
ment should be incorporated in treatment planning.
The future for MRT is indeed promising. A concerted effort 
from the multidisciplinary MRT community is now needed 
to propose new trials and to undertake preclinical research 
programmes to ensure the expansion and prosperity of this 
field.
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